Gamma-Aminobutyric acid
|
Basic information |
| Metabolite name | Gamma-Aminobutyric acid |
 | HMDB0000112 |
 |
C00334 |
 |
119 |
| Synonyms | γ-aminobutyric acid; |
| No. of studies | 119 |
|
Basic information |
| Metabolite name | Gamma-Aminobutyric acid |
| HMDB0000112 |
|
C00334 |
|
119 |
| Synonyms | γ-aminobutyric acid; |
| No. of studies | 119 |
|
Relationship between Gamma-Aminobutyric acid and depression (count: 119) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M044 | Type1 | CUMS + sham rTMS group vs. control + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M044 | Type1 | CUMS + sham rTMS group vs. control + sham rTMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M044 | Type3 | control + rTMS group vs. control + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M044 | Type3 | control + rTMS group vs. control + sham rTMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1018 | Type1 | MDD group vs. control group | Dorsolateral prefrontal cortex | Human | Down |
| Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1026 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1046 | Type3 | intraperitoneal ketamine group vs. intraperitoneal control group | Medial prefrontal cortex | BALB/cJ mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Brain | CD-1 mouse | Up |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M1086 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1090 | Type2 | CUMS + hyperbaric oxygen treatment group vs. CUMS group | Plasma | BALb/c mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1094 | Type1 | premenstrual dysphoric disorder liver-qi depression syndrome model group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1112 | Type4 | remitter group vs. non-remitter group, at baseline | Anterior cingulate cortex | Human | Down |
| Study M1126 | Type1 | ovariectomy group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1126 | Type2 | ovariectomy + middle dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1138 | Type2 | unpredictable subchronic stress + imipramine group vs. unpredictable subchronic stress group | Hippocampus | Swiss mouse | Up |
| Study M1141 | Type1 | austere environment group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M121 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M136 | Type2 | CUMS + moderate dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M144 | Type2 | CUMS + high dose of GSTT group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M148 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M162 | Type1 | depressed group vs. control group | Cerebrospinal fluid | Human | Down |
| Study M164 | Type1 | depressed group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M165 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Up |
| Study M170 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M170 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M177 | Type3 | scopolamine group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M177 | Type3 | Ro 25-6981 group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M177 | Type3 | ketamine group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M182 | Type1 | CUS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M182 | Type2 | CUS + riluzole group vs. CUS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M192 | Type3 | 4-week citalopram group vs. control group | Striatum | Sprague-Dawley rat | Up |
| Study M193 | Type2 | cLH + desipramine group vs. cLH group | Hippocampus | Sprague-Dawley rat | Up |
| Study M193 | Type2 | cLH + ESC group vs. cLH group | Hippocampus | Sprague-Dawley rat | Up |
| Study M193 | Type3 | ESC group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M216 | Type1 | depression group vs. control group | Occipital cortex | Human | Down |
| Study M226 | Type2 | SSRI-treated group post-treatment vs. pre-treatment | Occipital cortex | Human | Up |
| Study M231 | Type2 | ECT-treated depression post-treatment vs. pre-treatment | Occipital cortex | Human | Up |
| Study M233 | Type1 | depression group vs. control group | Occipital cortex | Human | Down |
| Study M242 | Type1 | depression group vs. control group | Occipital cortex | Human | Down |
| Study M254 | Type1 | depression group vs. control group | Dorsomedial/dorsal anterolateral prefrontal | Human | Down |
| Study M270 | Type1 | TRD group vs. control group | Occipital cortex | Human | Down |
| Study M297 | Type1 | depression group vs. control group | Occipital cortex | Human | Down |
| Study M324 | Type2 | rTMS-treated depression group post-treatment vs. pre-treatment | Medial prefrontal cortex | Human | Up |
| Study M328 | Type1 | depression group vs. control group | Anterior cingulate cortex/medial prefrontal cortex | Human | Down |
| Study M333 | Type2 | ketamine-treated depression group post-treatment vs. pre-treatment | Medial prefrontal cortex | Human | Up |
| Study M340 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M353 | Type1 | CUS group vs. control group | Anterior cingulate cortex | Sprague-Dawley rat | Up |
| Study M353 | Type2 | CUS + ketamine group vs. CUS group | Anterior cingulate cortex | Sprague-Dawley rat | Down |
| Study M353 | Type3 | ketamine group vs. control group | Anterior cingulate cortex | Sprague-Dawley rat | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M466 | Type1 | depression group vs. control group | Striatum | Human | Up |
| Study M473 | Type1 | high-fat diet group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M474 | Type1 | olfactory bulbectomy group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M481 | Type1 | SD group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M481 | Type2 | SD + ketamine group vs. SD group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M511 | Type1 | Susceptible group vs. control group | Hippocampus | Wistar/ST rat | Down |
| Study M514 | Type3 | ketamine group vs. vehicle group at 72 h | Hippocampus | C57BL/6 mouse | Up |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M549 | Type2 | MDD group, after vs. before rTMS treatment | Dorsolateral prefrontal cortex | Human | Up |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M553 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M553 | Type2 | CUMS + venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M558 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of volatile oils group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M559 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + high dose of terpenoids group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M563 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M563 | Type2 | CUMS + TCM group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M570 | Type1 | CMS group vs. control group | Cerebral cortex | BALB/c mouse | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M574 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M622 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + high dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M645 | Type2 | ketamine group, after vs. before treatment | Ventro-medial prefrontal cortex | Human | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M676 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M676 | Type2 | CVS + antibiotic group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M676 | Type2 | CVS + Chaihu-Shu-Gan-San group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type2 | CUMS + low dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M758 | Type1 | CUMS group vs. control group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of terpenoid group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of terpenoid group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of polysaccharide group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M759 | Type1 | depression group vs. control group | Ventromedial prefrontal cortex | Human | Up |
| Study M760 | Type1 | CUMS group vs. control group | Hippocampus | Rat | Down |
| Study M764 | Type1 | pentylenetetrazol group vs. control group | Hippocampus | Swiss albino mouse | Down |
| Study M764 | Type1 | pentylenetetrazol group vs. control group | Cortex | Swiss albino mouse | Down |
| Study M764 | Type2 | pentylenetetrazol + middle dose of embelin group vs. pentylenetetrazol group | Hippocampus | Swiss albino mouse | Up |
| Study M764 | Type2 | pentylenetetrazol + high dose of embelin group vs. pentylenetetrazol group | Hippocampus | Swiss albino mouse | Up |
| Study M764 | Type2 | pentylenetetrazol + high dose of embelin group vs. pentylenetetrazol group | Cortex | Swiss albino mouse | Up |
| Study M767 | Type1 | CUMS group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M767 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Down |
| Study M767 | Type1 | CUMS group vs. control group | Cortex | C57BL/6 mouse | Down |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Amygdala | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Cortex | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Striatum | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M771 | Type1 | CSDS group vs. control group | Faece | C57BL/6J mouse | Up |
| Study M782 | Type1 | MDD group vs. control group | Rostral anterior cingulate cortex | Human | Down |
| Study M797 | Type4 | remitter group change values vs. non-remitter group change values | Anterior cingulate cortex | Human | Up |
| Study M799 | Type1 | MDD group vs. control group | Middle temporal visual area | Human | Down |
| Study M808 | Type1 | pentetrazol group vs. control group | Hippocampus | Swiss mouse | Down |
| Study M808 | Type1 | pentetrazol group vs. control group | Prefrontal cortex | Swiss mouse | Down |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Down |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Hippocampus | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Hippocampus | Wistar rat | Up |
| Study M846 | Type1 | postpartum depression model group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Up |
| Study M854 | Type1 | MDD group vs. control group | Occipital cortex | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M935 | Type1 | chronic social isolation group vs. control group | Hippocampus | Wistar rat | Down |
| Study M935 | Type2 | chronic social isolation + tianeptine group vs. chronic social isolation group | Hippocampus | Wistar rat | Up |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Up |
| Study M942 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Amygdala | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Striatum | C57BL/6 mouse | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
| Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
| Study M983 | Type2 | adolescent MDD group, post-treatment vs. baseline | Plasma | Human | Down |
| Study M988 | Type1 | methionine sulfoximine group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |